نتایج جستجو برای: adenovirus vector

تعداد نتایج: 213919  

Journal: :European review for medical and pharmacological sciences 2014
P-Y Zhang L Hao Z-G Zhang B-Z Dong D Yang X-L Wang X-J Xuan Z Yan L Qing Z-D Shi D Liu C-H Han

OBJECTIVE The aim of this study was to construct a conditionally replicating adenovirus pPE3-SEA expressing staphylococcal enterotoxin A (SEA) gene. MATERIALS AND METHODS A full-length SEA gene fragment was cloned into pENTR12 plasmid to obtain a recombinant viral plasmid pENTR12-SEA. The pENTR12-SEA plasmid was co-transfected into HEK293 cells along with pPE3-ccdB, which encoded for the viru...

Journal: :Journal of virology 2009
Debanjan Dhar Jacqueline F Spencer Karoly Toth William S M Wold

Immune responses against adenovirus (Ad) vectors pose a possible concern for the outcome of treatment efficacy. To address the role of preexisting immunity in oncolytic Ad vector antitumor efficacy following intratumoral injection of vector as well as tumor-to-tissue spread of the vector, we employed the Syrian hamster model. These animals are immunocompetent, and their tumors and tissues are p...

2018
Peter Abbink Marinela Kirilova Michael Boyd Noe Mercado Zhenfeng Li Ramya Nityanandam Ovini Nanayakkara Rebecca Peterson Rafael A. Larocca Malika Aid Lawrence Tartaglia Tinaye Mutetwa Eryn Blass David Jetton Lori F. Maxfield Erica N. Borducchi Alexander Badamchi-Zadeh Scott Handley Guoyan Zhao Herbert W. Virgin Menzo J. Havenga Dan H. Barouch

Human and chimpanzee adenovirus vectors are being developed to circumvent preexisting antibodies against common adenovirus vectors such as Ad5. However, baseline immunity to these vectors still exists in human populations. Traditional cloning of new adenovirus vaccine vectors is a long and cumbersome process that takes 2 months or more and that requires rare unique restriction enzyme sites. Her...

Journal: :Journal of virology 2003
John W Schoggins Jason G D Gall Erik Falck-Pedersen

Altering adenovirus vector (Ad vector) targeting is an important goal for a variety of gene therapy applications and involves eliminating or reducing the normal tropism of a vector and retargeting through a distinct receptor-ligand pathway. The first step of Ad vector infection is high-affinity binding to a target cellular receptor. For the majority of adenoviruses and Ad vectors, the fiber cap...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1997
M A Kay L Meuse A M Gown P Linsley D Hollenbaugh A Aruffo H D Ochs C B Wilson

Although recombinant adenovirus vectors offer a very efficient means by which to transfer genetic information into cells in vivo, antigen-dependent immunity limits the duration of gene expression and prevents retreatment. Recombinant murine CTLA4Ig and anti-CD40 ligand antibody block costimulatory interactions between T cells and antigen presenting cells. We previously reported that murine CTLA...

Journal: :Vision Research 2008
Rajendra Kumar-Singh

The majority of recent preclinical gene therapy studies targeting the retina have used adeno-associated virus (AAV) as the gene transfer vector. However, AAV has several limitations including the ability to generate innate inflammatory responses, the ability to cause insertional mutagenesis at a frequency of up to 56% in some tissues and a limited cloning capacity of 4.8Kb. Furthermore, AAV is ...

2004
TANJA RAUMA-PINOLA Timo Hautala Heikki Ruskoaho Ken A. Lindstedt

Adenoviral gene transfer is a valuable tool in molecular biology research. In order to be an efficient and safe vector, adenovirus structure and infection mechanism as well as molecular biology of the used transgene need to be well studied. The aim of this study was to evaluate the role of adenovirus as a gene transfer vector from several perspectives. Adenovirus uses receptor-mediated endocyto...

Journal: :The New England journal of medicine 2015
Julie E Ledgerwood Nancy J Sullivan Barney S Graham

Julie E. Ledgerwood, D.O., Adam D. DeZure, M.D., Daphne A. Stanley, M.S., Laura Novik, M.A., Mary E. Enama, M.A., Nina M. Berkowitz, M.P.H., Zonghui Hu, Ph.D., Gyan Joshi, M.S., Aurélie Ploquin, Ph.D., Sandra Sitar, M.S., Ingelise J. Gordon, R.N., Sarah A. Plummer, C.R.N.P., LaSonji A. Holman, F.N.P., Cynthia S. Hendel, C.R.N.P., Galina Yamshchikov, M.S., Francois Roman, M.D., Alfredo Nicosia, ...

Journal: :Revista Brasileira de Ginecologia e Obstetrícia 2021

On January 17, 2021, two vaccines were approved by ANVISA for emergency use to help combat COVID-19: Coronavac and Covishield/Oxford. The first vaccine is composed of inactivated (killed) viruses, was produced the Chinese company Sinovac in Brazil, will be Butantã Institute (São Paulo). second an adenovirus non-replicating viral vector pharmaceutical Serum India partnership with AstraZeneca/Oxf...

Journal: :Journal of virology 2003
Shuji Kubo Kohnosuke Mitani

To achieve efficient and sustained gene expression, we developed a new lentivirus/adenovirus hybrid vector (LA vector) that encodes sequences required for production of a human immunodeficiency virus-based lentiviral vector (i.e., a lentiviral vector, a gag/pol/rev expression cassette, a tetracycline-inducible envelope cassette, and the tetracycline-inducible transcriptional activator cassette)...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید